nicholas vogelzang, md, explains how cabazitaxel should be used in various lines of treatment in mpc
Published 4 years ago • 172 plays • Length 1:53
Download video MP4
Download video MP3
Similar videos
-
5:20
nicholas vogelzang, md, on card study impressions comparing novel hormonal therapy to cabazitaxel
-
2:44
nicholas vogelzang, md, considers the dosing effects of cabazitaxel in clinical studies
-
1:52
nicholas j. vogelzang, md, on the benefit of adding docetaxel to 1st line, long-term hormone therapy
-
1:58
nicholas vogelzang, md, fasco, facp, regarding the evolution of adt in prostate cancer
-
1:42
nicholas j. vogelzang, md, fasco, facp, explains the influence of chaarted and stampede
-
1:15
nicholas vogelzang, md, fasco, facp, regarding sipuleucel-t in mcrpc
-
2:13
an introduction to advanced bladder cancer
-
4:29
comprehensive cancer dr vogelzang and the ferris family
-
1:53
dr. nicholas vogelzang discusses sequencing abiraterone and enzalutamide
-
42:50
dr giselle sholler, dfmo, when & how it is used
-
1:04
nicholas j. vogelzang, md, discusses the difference in mortality in the prosper and spartan trials
-
1:28
nicholas j. vogelzang, md, on immunotherapy & prostate cancer treatment algorithms
-
2:22
nicholas vogelzang, md, discusses re-emergence of dose reduced cabozantinib alezotuzumab in apc
-
1:30
cabazitaxel impacts sequencing strategies in prostate cancer
-
6:19
nicholas vogelzang, md, fasco, facp, describes the role of parp inhibitors advanced prostate cancer
-
1:47
nicholas j. vogelzang, md, fasco, facp, discusses resistance and advanced prostate cancer
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
25:37
developing next generation diagnostics for cancer
-
3:07
dr. vogelzang discusses the addition of chemotherapy to adt in men with prostate cancer
-
1:23
nicholas vogelzang, md, fasco, facp, regarding combination pembrolizumab and olaparib in mcrpc
-
11:06
utilizing tas102 and regorafenib for future studies
Clip.africa.com - Privacy-policy